Zimmer, Lisa
German Cancer Research Center · Essen University Hospital · Deutsches Konsortium für Translationale Krebsforschung
5 papers on CoChatORCID 0000-0002-3680-3521
Most cited papers
- Verified
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 3,151
- Verified
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 2,839
- Verified
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 1,039
- Verified
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H. M., Spano, J.-P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., et al. (2014) · Clinical Cancer Research
Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases
Cited by 71
- Verified
Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.
Dearden, H. C., Au, L., Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Curvietto, M., Khoo, C., Atkinson, V., Lo, S., et al. (2018) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 2
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free